meRfi®-GM
Siglecs (Sialic Acid-Binding-Type-Lectins)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Sialic acid containing ligands are recognized by unique Siglecs (Sialic Acid-Binding-Type-Lectins)
Sialic acid-binding Siglec receptors, a family of immune-modulating receptors, have been identified as inhibitors of antitumor activity in myeloid cells, natural killer cells, and T cells.
Novel aspects of Sialoglycans / Sialylated glycans recognition by the Siglec-like domains of [streptococcal SRR glycoproteins](brain://W6J4l5Pi9U-9lS7w43zYbg/Streptoco…
References (Sources)
- Altered tumor-cell glycosylation promotes metastasis
- Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors Siglec-7 and -9
- Loss of Siglec expression on T lymphocytes during human evolution
- Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9
- Novel aspects of sialoglycan recognition by the Siglec-like domains of streptococcal SRR glycoproteins
- Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
- The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunityReview